Annual EBITDA
-$5.07 M
+$1.23 M+19.56%
December 31, 2023
Summary
- As of February 26, 2025, LIXT annual EBITDA is -$5.07 million, with the most recent change of +$1.23 million (+19.56%) on December 31, 2023.
- During the last 3 years, LIXT annual EBITDA has fallen by -$1.81 million (-55.49%).
- LIXT annual EBITDA is now -15312.77% below its all-time high of -$32.90 thousand, reached on December 31, 2005.
Performance
LIXT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$985.00 K
+$21.80 K+2.17%
September 30, 2024
Summary
- As of February 26, 2025, LIXT quarterly EBITDA is -$985.00 thousand, with the most recent change of +$21.80 thousand (+2.17%) on September 30, 2024.
- Over the past year, LIXT quarterly EBITDA has stayed the same.
- LIXT quarterly EBITDA is now -725.40% below its all-time high of $157.50 thousand, reached on December 31, 2010.
Performance
LIXT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$3.98 M
+$33.50 K+0.84%
September 30, 2024
Summary
- As of February 26, 2025, LIXT TTM EBITDA is -$3.98 million, with the most recent change of +$33.50 thousand (+0.84%) on September 30, 2024.
- Over the past year, LIXT TTM EBITDA has stayed the same.
- LIXT TTM EBITDA is now -17981.82% below its all-time high of -$22.00 thousand, reached on March 31, 2006.
Performance
LIXT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
LIXT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +19.6% | 0.0% | 0.0% |
| 3 y3 years | -55.5% | +40.9% | +35.1% |
| 5 y5 years | -137.2% | +40.9% | +35.1% |
LIXT EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +24.6% | -2.2% | +51.4% | at high | +40.8% |
| 5 y | 5-year | -107.8% | +24.6% | -250.8% | +51.4% | -86.8% | +40.8% |
| alltime | all time | <-9999.0% | +24.6% | -725.4% | +51.4% | <-9999.0% | +40.8% |
Lixte Biotechnology Holdings EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$985.00 K(-2.2%) | -$3.98 M(-0.8%) |
| Jun 2024 | - | -$1.01 M(+4.4%) | -$4.01 M(-14.1%) |
| Mar 2024 | - | -$964.10 K(-5.7%) | -$4.67 M(-7.9%) |
| Dec 2023 | -$5.07 M(-19.6%) | -$1.02 M(+0.4%) | -$5.07 M(-10.7%) |
| Sep 2023 | - | -$1.02 M(-38.9%) | -$5.68 M(-7.5%) |
| Jun 2023 | - | -$1.67 M(+22.2%) | -$6.13 M(+2.0%) |
| Mar 2023 | - | -$1.36 M(-16.2%) | -$6.01 M(-4.6%) |
| Dec 2022 | -$6.30 M(-6.2%) | -$1.63 M(+10.3%) | -$6.30 M(-5.9%) |
| Sep 2022 | - | -$1.48 M(-4.5%) | -$6.70 M(+3.7%) |
| Jun 2022 | - | -$1.55 M(-6.6%) | -$6.46 M(-2.8%) |
| Mar 2022 | - | -$1.65 M(-18.3%) | -$6.65 M(-1.1%) |
| Dec 2021 | -$6.72 M(+106.1%) | -$2.02 M(+63.5%) | -$6.72 M(+20.0%) |
| Sep 2021 | - | -$1.24 M(-28.5%) | -$5.60 M(-6.1%) |
| Jun 2021 | - | -$1.73 M(+0.4%) | -$5.96 M(+29.5%) |
| Mar 2021 | - | -$1.73 M(+91.0%) | -$4.60 M(+41.1%) |
| Dec 2020 | -$3.26 M(+33.6%) | -$903.30 K(-43.6%) | -$3.26 M(+23.6%) |
| Sep 2020 | - | -$1.60 M(+329.3%) | -$2.64 M(+23.9%) |
| Jun 2020 | - | -$373.10 K(-2.6%) | -$2.13 M(-10.7%) |
| Mar 2020 | - | -$383.20 K(+36.5%) | -$2.38 M(-2.3%) |
| Dec 2019 | -$2.44 M(+14.1%) | -$280.80 K(-74.3%) | -$2.44 M(-2.8%) |
| Sep 2019 | - | -$1.09 M(+74.1%) | -$2.51 M(+2.4%) |
| Jun 2019 | - | -$627.90 K(+43.1%) | -$2.45 M(+11.7%) |
| Mar 2019 | - | -$438.70 K(+24.6%) | -$2.20 M(+2.8%) |
| Dec 2018 | -$2.14 M(+18.1%) | -$352.00 K(-66.0%) | -$2.14 M(-3.7%) |
| Sep 2018 | - | -$1.03 M(+178.1%) | -$2.22 M(+34.7%) |
| Jun 2018 | - | -$371.90 K(-2.1%) | -$1.65 M(+5.0%) |
| Mar 2018 | - | -$379.80 K(-12.3%) | -$1.57 M(-13.3%) |
| Dec 2017 | -$1.81 M(-15.2%) | -$433.00 K(-6.5%) | -$1.81 M(-4.4%) |
| Sep 2017 | - | -$463.20 K(+58.1%) | -$1.89 M(-8.9%) |
| Jun 2017 | - | -$292.90 K(-52.8%) | -$2.08 M(-11.2%) |
| Mar 2017 | - | -$620.60 K(+20.2%) | -$2.34 M(+9.6%) |
| Dec 2016 | -$2.13 M(-19.3%) | -$516.30 K(-20.2%) | -$2.13 M(-4.4%) |
| Sep 2016 | - | -$647.10 K(+16.6%) | -$2.23 M(-5.6%) |
| Jun 2016 | - | -$555.00 K(+33.2%) | -$2.37 M(+2.3%) |
| Mar 2016 | - | -$416.60 K(-32.1%) | -$2.31 M(-12.7%) |
| Dec 2015 | -$2.65 M | -$613.90 K(-21.3%) | -$2.65 M(-2.0%) |
| Sep 2015 | - | -$779.70 K(+55.7%) | -$2.70 M(+11.5%) |
| Jun 2015 | - | -$500.70 K(-33.4%) | -$2.42 M(-0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$752.20 K(+12.5%) | -$2.44 M(+1.5%) |
| Dec 2014 | -$2.40 M(+74.8%) | -$668.70 K(+33.4%) | -$2.40 M(+14.8%) |
| Sep 2014 | - | -$501.40 K(-3.1%) | -$2.09 M(+9.9%) |
| Jun 2014 | - | -$517.30 K(-27.7%) | -$1.91 M(+8.5%) |
| Mar 2014 | - | -$715.80 K(+99.4%) | -$1.76 M(+27.8%) |
| Dec 2013 | -$1.37 M(-61.6%) | -$359.00 K(+14.7%) | -$1.37 M(+6.4%) |
| Sep 2013 | - | -$313.10 K(-15.1%) | -$1.29 M(-56.3%) |
| Jun 2013 | - | -$368.80 K(+10.5%) | -$2.96 M(-11.0%) |
| Mar 2013 | - | -$333.90 K(+21.1%) | -$3.32 M(-7.2%) |
| Dec 2012 | -$3.58 M(+73.1%) | -$275.70 K(-86.1%) | -$3.58 M(-14.2%) |
| Sep 2012 | - | -$1.98 M(+169.5%) | -$4.17 M(+54.9%) |
| Jun 2012 | - | -$734.00 K(+24.0%) | -$2.69 M(+16.7%) |
| Mar 2012 | - | -$591.90 K(-32.0%) | -$2.31 M(+11.6%) |
| Dec 2011 | -$2.07 M(+134.5%) | -$869.90 K(+74.3%) | -$2.07 M(+98.7%) |
| Sep 2011 | - | -$499.20 K(+43.5%) | -$1.04 M(+13.1%) |
| Jun 2011 | - | -$347.80 K(-0.9%) | -$920.10 K(+4.3%) |
| Mar 2011 | - | -$351.10 K(-322.9%) | -$882.30 K(+0.1%) |
| Dec 2010 | -$881.70 K(-43.1%) | $157.50 K(-141.6%) | -$881.70 K(-45.4%) |
| Sep 2010 | - | -$378.70 K(+22.2%) | -$1.61 M(-4.4%) |
| Jun 2010 | - | -$310.00 K(-11.6%) | -$1.69 M(+4.1%) |
| Mar 2010 | - | -$350.50 K(-39.0%) | -$1.62 M(+4.6%) |
| Dec 2009 | -$1.55 M(+21.8%) | -$575.00 K(+26.9%) | -$1.55 M(+25.5%) |
| Sep 2009 | - | -$453.10 K(+86.5%) | -$1.24 M(-3.4%) |
| Jun 2009 | - | -$243.00 K(-12.9%) | -$1.28 M(+22.2%) |
| Mar 2009 | - | -$279.00 K(+7.1%) | -$1.05 M(-17.8%) |
| Dec 2008 | -$1.27 M(-23.2%) | -$260.50 K(-47.5%) | -$1.27 M(-3.0%) |
| Sep 2008 | - | -$496.30 K(+4495.4%) | -$1.31 M(-24.5%) |
| Jun 2008 | - | -$10.80 K(-97.9%) | -$1.74 M(-8.8%) |
| Mar 2008 | - | -$505.30 K(+68.5%) | -$1.91 M(+14.9%) |
| Dec 2007 | -$1.66 M(+268.9%) | -$299.90 K(-67.5%) | -$1.66 M(+10.1%) |
| Sep 2007 | - | -$921.70 K(+414.3%) | -$1.51 M(+115.1%) |
| Jun 2007 | - | -$179.20 K(-30.5%) | -$700.60 K(+10.3%) |
| Mar 2007 | - | -$257.70 K(+73.8%) | -$635.30 K(+59.0%) |
| Dec 2006 | -$449.50 K(+1266.3%) | -$148.30 K(+28.5%) | -$399.60 K(+59.0%) |
| Sep 2006 | - | -$115.40 K(+1.3%) | -$251.30 K(+84.9%) |
| Jun 2006 | - | -$113.90 K(+417.7%) | -$135.90 K(+517.7%) |
| Mar 2006 | - | -$22.00 K | -$22.00 K |
| Dec 2005 | -$32.90 K | - | - |
FAQ
- What is Lixte Biotechnology Holdings annual EBITDA?
- What is the all time high annual EBITDA for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings annual EBITDA year-on-year change?
- What is Lixte Biotechnology Holdings quarterly EBITDA?
- What is the all time high quarterly EBITDA for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings quarterly EBITDA year-on-year change?
- What is Lixte Biotechnology Holdings TTM EBITDA?
- What is the all time high TTM EBITDA for Lixte Biotechnology Holdings?
- What is Lixte Biotechnology Holdings TTM EBITDA year-on-year change?
What is Lixte Biotechnology Holdings annual EBITDA?
The current annual EBITDA of LIXT is -$5.07 M
What is the all time high annual EBITDA for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high annual EBITDA is -$32.90 K
What is Lixte Biotechnology Holdings annual EBITDA year-on-year change?
Over the past year, LIXT annual EBITDA has changed by +$1.23 M (+19.56%)
What is Lixte Biotechnology Holdings quarterly EBITDA?
The current quarterly EBITDA of LIXT is -$985.00 K
What is the all time high quarterly EBITDA for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high quarterly EBITDA is $157.50 K
What is Lixte Biotechnology Holdings quarterly EBITDA year-on-year change?
Over the past year, LIXT quarterly EBITDA has changed by $0.00 (0.00%)
What is Lixte Biotechnology Holdings TTM EBITDA?
The current TTM EBITDA of LIXT is -$3.98 M
What is the all time high TTM EBITDA for Lixte Biotechnology Holdings?
Lixte Biotechnology Holdings all-time high TTM EBITDA is -$22.00 K
What is Lixte Biotechnology Holdings TTM EBITDA year-on-year change?
Over the past year, LIXT TTM EBITDA has changed by $0.00 (0.00%)